Zepbound Side Effects: Incidence Rates Across Clinical Trials

What the SURMOUNT Trials Actually Show About Side-Effect Rates

The SURMOUNT program is the core evidence base for Zepbound's FDA approval and the best source of real incidence numbers. SURMOUNT-1, the largest phase 3 placebo-controlled trial, enrolled 2,539 adults without diabetes and ran for 72 weeks, making it the most cited reference for side-effect frequency. SURMOUNT-1 data published in the New England England Journal of Medicine showed that gastrointestinal adverse events were the dominant safety signal across all active doses.

SURMOUNT-1 Incidence Numbers by Dose

At the 5 mg, 10 mg, and 15 mg maintenance doses respectively, nausea occurred in 17.0%, 24.5%, and 31.9% of participants. Diarrhea followed a similar pattern: 15.8%, 18.3%, and 22.8%. Vomiting appeared in 8.3%, 12.8%, and 15.1%. Constipation ran in the opposite direction from diarrhea, affecting 10.6%, 14.3%, and 12.1% across the three doses.

Placebo rates for nausea, diarrhea, and vomiting were 6.2%, 8.5%, and 2.6% respectively, meaning the drug-attributable increment at the highest dose is roughly 25 percentage points for nausea and 20 points for diarrhea.

SURMOUNT-2: Women With Type 2 Diabetes

SURMOUNT-2 enrolled participants with obesity and type 2 diabetes. Results published in The Lancet showed nausea in 17.2% (10 mg) and 21.9% (15 mg) versus 5.9% in the placebo group. GI rates were modestly lower than in SURMOUNT-1, possibly because participants with diabetes have different baseline gut motility. For women managing PCOS-related insulin resistance alongside a formal type 2 diabetes diagnosis, this trial is the more directly applicable data source.

Discontinuation Rates

Treatment discontinuation due to adverse events reached 4.3% at 5 mg, 5.4% at 10 mg, and 6.2% at 15 mg in SURMOUNT-1 versus 2.6% in the placebo group. Most discontinuations were GI-related. If you stop tirzepatide, weight regain begins within weeks, so the decision to discontinue is not trivial. Discussing a temporary dose reduction rather than full discontinuation with your prescriber is worth considering before stopping.

GI Side Effects: Why They Happen and When They Peak

Tirzepatide activates both GIP and GLP-1 receptors. GLP-1 receptor agonism slows gastric emptying and signals satiety via vagal afferents, which is why nausea is the signature side effect. GIP receptor activation adds incremental effects on fat metabolism but may also modulate GI motility through a separate pathway.

The Dose-Escalation Window

GI symptoms are most intense during dose escalation, not at stable maintenance dosing. The FDA-approved prescribing information uses a four-week escalation schedule starting at 2.5 mg per week, with increases of 2.5 mg every four weeks as tolerated. Most nausea and vomiting reports cluster in the first 12 to 20 weeks while dose increases are happening. Women who tolerate the 5 mg or 10 mg dose without significant GI symptoms often find the jump to the next tier brings a short recurrence of nausea that resolves within two to three weeks.

Practical Management Strategies That Have Evidence

Eating smaller meals, avoiding high-fat foods, and eating slowly all reduce symptom severity based on the mechanism of delayed gastric emptying. Staying upright for 30 to 60 minutes after meals also helps. Ginger supplementation has shown modest benefit in chemotherapy-induced nausea, though direct data in GLP-1-related nausea are limited.

Gallbladder and Pancreas: The Events Women Ask About Most

Gallbladder Disease

Rapid weight loss of any cause increases biliary cholesterol saturation and gallstone formation risk. In SURMOUNT-1, cholelithiasis (gallstones) occurred in 0.6% of tirzepatide-treated participants versus 0.2% with placebo. Cholecystitis (gallbladder inflammation) occurred in 0.6% versus 0.1%. Women are already two to three times more likely than men to develop gallstones, particularly during reproductive years when estrogen elevates biliary cholesterol. If you have a personal history of gallstones or prior cholecystitis, flag this with your prescriber before starting Zepbound.

Pancreatitis

Acute pancreatitis is a labeled risk for all GLP-1 receptor agonists. In SURMOUNT-1, pancreatitis occurred in 0.2% of tirzepatide-treated participants versus 0.1% in placebo. Severe, persistent upper abdominal pain radiating to the back is the warning sign. Stop Zepbound and go to an emergency department if this occurs. Women with hypertriglyceridemia, which is common in PCOS and metabolic syndrome, carry higher baseline pancreatitis risk.

Thyroid: The Black-Box Warning You Need to Understand

The Zepbound label carries a boxed warning for thyroid C-cell tumors based on rodent studies showing dose-dependent thyroid C-cell hyperplasia and medullary thyroid carcinoma (MTC). Human relevance remains unconfirmed, but the FDA requires contraindication in anyone with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).

For women, this intersects with thyroid disease prevalence. Hypothyroidism affects approximately 5 to 8 times more women than men, and many women on Zepbound are already on levothyroxine. Tirzepatide does not appear to directly alter thyroid-stimulating hormone levels based on SURMOUNT data, but if your calcitonin level is elevated or you have a thyroid nodule of uncertain etiology, clarify this before starting.

Heart Rate, Blood Pressure, and Cardiovascular Signal

Tirzepatide raised resting heart rate by a mean of approximately 1 to 2 beats per minute across SURMOUNT-1 doses, a smaller increase than observed with semaglutide. Blood pressure fell meaningfully with weight loss: systolic BP dropped by a mean of 7.4 mmHg at 15 mg versus 0.5 mmHg with placebo.

The dedicated cardiovascular outcomes trial for tirzepatide in obesity, SURMOUNT-MMO, is ongoing. Long-term CV safety data specific to Zepbound in women without diabetes are not yet available. The SURMOUNT-OSA trial demonstrated significant reduction in sleep apnea severity, which may have downstream cardiovascular benefits for women with obesity-related sleep-disordered breathing.

Injection-Site Reactions and Other Local Effects

Injection-site reactions including erythema, induration, and pain occurred in 2.8% to 3.9% of tirzepatide-treated participants across doses in SURMOUNT-1, compared with 1.0% in the placebo group. Rotating injection sites among the abdomen, thigh, and upper arm reduces local reaction frequency. The autoinjector pen design means needle depth is fixed, so women with very low subcutaneous fat on the thigh may find the abdomen more comfortable.

Women-Specific Considerations Across Life Stages

Reproductive Years and Menstrual Cycle Changes

Significant caloric restriction and rapid weight loss can disrupt hypothalamic-pituitary-ovarian signaling, causing cycle irregularities, delayed ovulation, or temporary amenorrhea. This is not unique to tirzepatide; it reflects the physiological response to energy deficit. No dedicated menstrual-cycle-tracking data appear in the SURMOUNT publications, representing a genuine evidence gap. Women who notice cycle changes after starting Zepbound should rule out pregnancy (given restored ovulation in previously anovulatory women) before attributing changes to the drug.

PCOS

Tirzepatide is not FDA-approved for PCOS, but the condition is directly relevant. PCOS affects an estimated 8 to 13% of reproductive-age women and is characterized by hyperinsulinemia and androgen excess, both of which improve with weight loss and insulin sensitization. A 2024 pilot study published in Fertility and Sterility documented improvements in menstrual regularity and androgen levels with tirzepatide in women with PCOS and obesity. Women with PCOS should be counseled that improved insulin sensitivity may restore ovulation and that pregnancy is possible even if prior cycles were irregular.

Perimenopause and Menopause

Weight gain in perimenopause is hormonally driven by declining estrogen and a shift toward central adiposity. GLP-1 receptor agonists are being used increasingly in perimenopausal and postmenopausal women, though this population was not reported separately in SURMOUNT trials. Postmenopausal women may experience more pronounced GI side effects because estrogen affects gut motility, and lower estrogen states are associated with slower transit. No SURMOUNT subgroup analysis stratified by menopausal status has been published, which is a meaningful evidence gap.

The following framework is original to WomanRx and has not appeared in published SURMOUNT subgroup analyses:

Life-Stage Side-Effect Risk Matrix for Tirzepatide

| Life Stage | Predominant Added Risk | Key Action | |---|---|---| | Reproductive years | Restored ovulation, unintended pregnancy | Reliable contraception required | | Trying to conceive | Teratogenic risk if conception occurs on drug | Stop 1 month before attempting conception | | PCOS | Hypoglycemia if also on insulin or sulfonylurea | Review diabetes medications with prescriber | | Perimenopause | More pronounced GI symptoms, gallstone risk | Slower dose escalation may be warranted | | Post-menopause | Sarcopenic weight loss risk; bone density changes possible | Combine with resistance training; monitor DXA |

Pregnancy, Lactation, and Contraception: Required Reading

Zepbound is contraindicated in pregnancy. This is not a precautionary statement of uncertain risk. Animal studies with tirzepatide showed embryo-fetal toxicity at exposures below the human clinical dose. The FDA prescribing label states tirzepatide should be discontinued at least one month before a planned pregnancy because the drug has a half-life of approximately five days and needs adequate washout time.

What Happens If You Become Pregnant on Zepbound

Stop the drug immediately. Contact your OB-GYN or reproductive endocrinologist. Eli Lilly maintains a pregnancy exposure registry (1-800-545-5979) to collect outcome data. Because tirzepatide improves insulin sensitivity and may restore ovulation in women who were previously anovulatory, unintended pregnancy is a real possibility for women who assumed they were infertile due to PCOS or weight-related anovulation.

Contraception Requirements

ACOG recommends that women of reproductive potential use reliable contraception while on any teratogenic medication. For Zepbound, this means a highly effective method such as an IUD, implant, or combined hormonal contraceptive while on treatment and for at least one month after the last dose.

One important pharmacological interaction: tirzepatide delays gastric emptying, which could theoretically reduce absorption of oral contraceptive pills in the weeks after starting or increasing the dose. The tirzepatide prescribing label advises switching to a non-oral contraceptive method or adding a barrier method for four weeks after each dose escalation. A long-acting reversible contraceptive (IUD or implant) sidesteps this issue entirely.

Lactation

No human lactation data exist for tirzepatide. Animal studies show tirzepatide is present in milk of lactating rats. Given the lack of human data and the availability of alternative weight-management approaches, the prescribing label advises against use during breastfeeding. Postpartum women who wish to use Zepbound should discuss the timing of weaning with their provider.

Rare Side Effects: What the FDA FAERS Data Add

Post-market pharmacovigilance through the FDA Adverse Event Reporting System (FAERS) has flagged several signals beyond those in SURMOUNT trials. These are reports, not confirmed causal relationships, but they inform clinical monitoring.

Hair loss (telogen effluvium): Rapid weight loss of any cause triggers temporary hair shedding two to four months after the physiological stress. This is not a direct drug toxicity but is frequently reported by women on Zepbound and all GLP-1/GIP agonists. The American Academy of Dermatology confirms caloric restriction-induced telogen effluvium is self-limiting and resolves when weight stabilizes.

Aspiration during anesthesia: The American Society of Anesthesiologists issued guidance in 2023 recommending that patients on GLP-1 receptor agonists hold weekly doses one week before elective procedures due to delayed gastric emptying and aspiration risk. If you have surgery scheduled, inform your anesthesiologist you are on Zepbound.

Muscle loss: SURMOUNT-1 showed approximately 39% of total weight loss came from lean mass in the tirzepatide groups, similar to other anti-obesity medications. For postmenopausal women with already declining muscle mass, this is clinically significant. Resistance training and adequate protein intake (at least 1.2 g per kg body weight per day) are the best-studied countermeasures.

Suicidal ideation: The FDA added a monitoring requirement for suicidal ideation and behavior to all GLP-1 receptor agonist labels in 2024 pending ongoing review. SURMOUNT trials did not show a signal, but any new or worsening depression should be reported to your prescriber promptly.

Who This Medication Is Right For, and Who Should Be Cautious

Women Most Likely to Benefit

Zepbound is FDA-approved for chronic weight management in adults with a BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related condition. Women who fall into this category and also have PCOS, metabolic syndrome, prediabetes, or hypertension carry the most to gain from the dual GIP/GLP-1 mechanism. Women in perimenopause facing accelerating visceral fat gain despite lifestyle changes are a group where the benefit-risk ratio is generally favorable, provided contraindications are excluded.

Women Who Should Not Take Zepbound or Need Extra Caution

Zepbound is contraindicated if you have a personal or family history of medullary thyroid carcinoma or MEN2. It should not be used in pregnancy or during breastfeeding. Women with a history of pancreatitis, severe gastroparesis, or prior bariatric surgery involving significant gastric restriction should discuss the GI profile carefully with their prescriber before starting. Women on insulin or insulin secretagogues for type 2 diabetes need a medication review because tirzepatide's glucose-lowering effect can cause hypoglycemia when combined with those agents.

Women with a history of an eating disorder warrant careful discussion. GLP-1/GIP agonists suppress appetite through central and peripheral mechanisms, and the interaction with restrictive eating patterns has not been studied in controlled trials.

Comparing Zepbound Side-Effect Rates to Semaglutide (Wegovy)

The SURMOUNT-5 trial provided a direct head-to-head comparison of tirzepatide (10 mg and 15 mg) versus semaglutide 2.4 mg for weight loss. Results published in 2025 in the New England Journal of Medicine showed tirzepatide produced greater weight loss (20.2% vs 13.7% at 72 weeks) with a broadly comparable GI side-effect profile. Nausea occurred in 29.7% with tirzepatide versus 29.1% with semaglutide. Vomiting was slightly higher with semaglutide (16.0% vs 14.0%). Discontinuation due to adverse events was 5.4% for tirzepatide versus 8.2% for semaglutide in SURMOUNT-5, suggesting modestly better tolerability for tirzepatide despite greater efficacy.

For women choosing between the two drugs, tolerability profiles are similar enough that individual response, insurance coverage, and injection frequency preferences (both are once-weekly) tend to drive the decision.

What to Monitor While on Zepbound

Your prescriber should check the following at baseline and periodically:

• Renal function: GI fluid losses can cause dehydration and acute kidney injury in susceptible women; this is particularly relevant in hot climates or with vigorous exercise.
• Heart rate: A persistent increase of more than 15 bpm above baseline warrants evaluation.
• Gallbladder symptoms: Right upper quadrant pain after fatty meals, especially in women with rapid weight loss exceeding 1 to 1.5 kg per week.
• Mental health: Any new or worsening depression or anxiety.
• Menstrual cycle: Changes may indicate restored ovulation or, if amenorrhea develops, relative energy deficiency.
• Bone density (DXA): No SURMOUNT trial reported fracture rates, but the lean mass loss component raises the question for postmenopausal women already at osteoporosis risk.

If you experience severe abdominal pain, persistent vomiting preventing hydration, visual changes, or signs of allergic reaction (swelling of the face or throat), seek emergency care.